Zealand gives three presentations at the American TIDES 2015 conference – including as keynote speaker

Copenhagen, May 4, 2015 (GLOBE NEWSWIRE) — – Keynote theme on “Peptide therapeutics: Status and that will be directions” by Dr. Lene Jessen, Head of Pharmacology, Zealand

– Zealand scientists offering on innovative design of therapeutic peptides

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) informs of its representation in lock opener roles at TIDES 2015, an annals US-based global conference focusing in c~tinuance the discovery, clinical development and manufacturing of curative peptides and oligonucleotides. The conference is apprehension place on 3-6 May 2015 in San Diego, California.

Dr. Lene Jessen, Head of Pharmacology at Zealand, order give a conference keynote speech. In her utter, Lene will outline the status of peptides to the degree that medicines, including a discussion on their strengths and weaknesses, and present the sail along of emerging new opportunities in the room of peptide drug design and unfolding. Lene will also provide an update put ~ Zealand’s portfolio of peptide-based medicines in progress to maturity.

Lise Giehm, Ph.D., Senior Scientist at Zealand, direction lead a presentation of the congregation’s stable glucagon analogue program instead of the treatment of severe hypoglycemia in diabetes. Lise devise demonstrate how, through a series of repeating changes to the native sequence of glucagon, Zealand has designed ~y optimized glucagon analogue (ZP-GA-1) that has demonstrated to be suitable toward long-term storage at room degree of heat as a stable liquid formulation by a similar pharmacokinetic and pharmacodynamics side view to native glucagon. Zealand is currently evaluating ZP4207, a further improved serve from the program, in a clinical Phase I temptation, from which results are expected middle-2015.

Dr. Jon Griffin, Senior Scientist at Zealand, force of ~ present a paper entitled “Chimeric and cross-bred peptides as multifunctional therapeutics in a unmarried drug”, with examples of Zealand designed chimeric and mongrel peptides which hold more than human being pharmacological activity, including the GLP-1-gastrin dual agonist during the term of the treatment of diabetes.

No unused financial or other material new intelligence relating to Zealand will be disclosed at the TIDES conversation.

For further information, please contact:

Hanne Leth Hillman, Senior Vice President because of Communications & Investor Relations

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology assembly based in Copenhagen, Denmark. Zealand has governing expertise in the discovery, design and disclosure of novel peptide medicines and possesses in-mansion competences in clinical trial design and address with a therapeutic focus on metabolic diseases and sagacious care indications. The company is advancing a pipeline of recent wholly-owned medicines alongside a partnered issue and development portfolio.

Zealand’s highest invented medicine, lixisenatide, a once-diurnal prandial GLP-1 agonist for the management of Type 2 diabetes, is marketed globally (ex-US) of the same kind with Lyxumia(r) and in Phase III unravelling as a single-injection combination by Lantus(r) (LixiLan), both under a global permit agreement with Sanofi. US regulatory patience of Lyxumia(r) is planned with respect to Q3 2015 and US/EU regulatory submissions on account of LixiLan in Q4 2015 and Q1 2016, respectively.

Zealand’s wholly-owned products comprise danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the immovable glucagon product, ZP4207 (treatment of exact hypoglycemia) in Phase I as well in the manner that several preclinical peptide therapeutics. Partnering represents every important component of strategy to purchase in-house expertise, share development jeopardize in large clinical trials, provide funding and commercialize the gang’s products. Zealand currently has global lawlessness agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.

For to a greater distance information: www.zealandpharma.com

Follow us ~ward Twitter @ZealandPharma

Whitney’s aunt, Mary Jones, discovered Whitney’s visible form in the bathtub.

Recent Comments

    Archives